Theralase Releases Annual General Meeting Video

Toronto, Ontario – November 25, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTCBB) announced today that it has released a video of the presentations conducted at the Theralase 2013 Annual General Meeting (“AGM”), held on November 14, 2014. The presentations were conducted by Theralase President and CEO, Roger Dumoulin-White and Dr. Lothar Lilge, Professor in the Department of Medical Biophysics University of Toronto and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network (“UHN”).

Mr. Dumoulin-White presented the strategic vision for both the Therapeutic Laser Technology (“TLT”) division and the Photo Dynamic Therapy (“PDT”) anti-cancer division, while Dr. Lilge presented on the scientific and preclinical data supporting the recent advances in the PDT division. Both Mr. Dumoulin-White and Dr. Lilge were available to answer questions from the audience at the end of their presentations.

Dr. Lothar Lilge PhD, Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network stated that, “It is always enjoyable to present the scientific data supporting the Theralase anti-cancer technology to a diversified audience and to address their questions to expand their knowledge and understanding of what this pivotal technology is able to accomplish in pre-clinical research and what it may be capable of in human clinical trials.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “The Theralase AGM has always been an excellent forum for Theralase to discuss its accomplishments over the last year and to more fully explain its vision for both the TLT and PDT division for the ensuing year. By presenting our strategic vision and addressing the questions of the audience, we are able to better communicate the Company’s strategic direction.”

Watch the Presentation Videos:


About Theralase Technologies Inc.

Founded in 1994, Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Link®) designs, manufactures and markets patented super-pulsed laser technology used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 1,200 systems to licensed healthcare practitioners, including: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been very successful in healing nerve, muscle and joint conditions in clinical practice and now Theralase’s scientists and clinicians are investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to the DNA of cancer cells and when light activated, destroy the cancer cells.

Additional information is available at and .

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.


For More Information:

Roger Dumoulin-White

President & CEO, Theralase Technologies Inc.

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225